FluoroPharma Medical (FluoroPharma Medical) EBIT per Share : $-0.03 (TTM As of Dec. 2016)

View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical EBIT per Share?

FluoroPharma Medical's EBIT per Share for the three months ended in Dec. 2016 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2016 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for FluoroPharma Medical's EBIT per Share or its related term are showing as below:

FPMI's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

FluoroPharma Medical's EBIT for the three months ended in Dec. 2016 was $0.07 Mil.

FluoroPharma Medical EBIT per Share Historical Data

The historical data trend for FluoroPharma Medical's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical EBIT per Share Chart

FluoroPharma Medical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

EBIT per Share

Get a 7-Day Free Trial

-0.18

-0.23

-0.14

-0.08

-0.02

FluoroPharma Medical Quarterly Data
	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16
EBIT per Share	Get a 7-Day Free Trial															-0.03	-0.04	-0.01	0.01	-

FluoroPharma Medical EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

FluoroPharma Medical's EBIT per Share for the fiscal year that ended in Dec. 2016 is calculated as

	EBIT per Share		(A: Dec. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.788	/	33.556
=	-0.02

FluoroPharma Medical's EBIT per Share for the quarter that ended in Dec. 2016 is calculated as

	EBIT per Share		(Q: Dec. 2016 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0.069	/	34.027
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

FluoroPharma Medical (OTCPK:FPMI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

FluoroPharma Medical EBIT per Share Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

FluoroPharma Medical (FluoroPharma Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042

Website

http://www.fluoropharma.com

FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.

Executives

Johan M. Spoor

director, officer: CEO, PRESIDENT, CHAIRMAN

500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus

FPMI Restructures CardioPET License With Massachusetts General Hospital

By Marketwired Marketwired • 09-27-2018